Genomic Health Oncotype DX recommended in NICE guidance

theflyonthewall.com

The U.K.'s National Institute for Health and Clinical Excellence, or NICE, issued draft guidance on four tests used to guide decisions about the use of chemotherapy in people with early breast cancer following consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX, Genomic Health (GHDX). The draft guidance recommends the use of Oncotype DX in people with oestrogen receptor positive, lymph node negative and human epidermal growth factor receptor 2 negative early breast cancer, who are assessed as being at intermediate risk, to guide chemotherapy decisions where the manufacturer provides it at the price offered through the confidential access proposal. The recommendation for Oncotype DX applies to people assessed as being at intermediate risk of distant recurrence by decision making tools/protocols currently in use in the NHS and where the decision to prescribe chemotherapy remains unclear, NICE said. The draft guidance also highlights that it has not been able to support the routine use of the IHC4, MammaPrint or Mammostrat tests but recommends that they are used in a research setting to collect evidence about potentially important clinical outcomes and to determine the ability of the tests to predict the efficacy of chemotherapy in people with early breast cancer.

Rates

View Comments